Next Article in Journal
Berberine Targets PKM2 to Activate the t-PA-Induced Fibrinolytic System and Improves Thrombosis
Previous Article in Journal
RP-CAD for Lipid Quantification: Systematic Method Development and Intensified LNP Process Characterization
Previous Article in Special Issue
Small Molecules Incorporating Privileged Amidine Moiety as Potential Hits Combating Antibiotic-Resistant Bacteria
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

From the “One-Molecule, One-Target, One-Disease” Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections

1
Aix-Marseille Université, CNRS, ICR UMR_7273, LPCR, Faculté de Pharmacie, 13005 Marseille, France
2
Unité des Virus Émergents (UVE: Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA), 13005 Marseille, France
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(9), 1218; https://doi.org/10.3390/ph17091218
Submission received: 11 July 2024 / Revised: 9 September 2024 / Accepted: 11 September 2024 / Published: 16 September 2024
(This article belongs to the Special Issue Hit to Lead Design of New Anti-Infective Drugs)

Abstract

Non-polio enteroviruses (NPEVs), namely coxsackieviruses (CV), echoviruses (E), enteroviruses (EV), and rhinoviruses (RV), are responsible for a wide variety of illnesses. Some infections can progress to life-threatening conditions in children or immunocompromised patients. To date, no treatments have been approved. Several molecules have been evaluated through clinical trials without success. To overcome these failures, the multi-target directed ligand (MTDL) strategy could be applied to tackle enterovirus infections. This work analyzes registered clinical trials involving antiviral drugs to highlight the best candidates and develops filters to apply to a selection for MTDL synthesis. We explicitly stated the methods used to answer the question: which solution can fight NPEVs effectively? We note the originality and relevance of this proposal in relation to the state of the art in the enterovirus-inhibitors field. Several combinations are possible to broaden the antiviral spectrum and potency. We discuss data related to the virus and data related to each LEAD compound identified so far. Overall, this study proposes a perspective on different strategies to overcome issues identified in clinical trials and evaluate the “MTDL” potential to improve the efficacy of drugs, broaden the antiviral targets, possibly reduce the adverse effects, drug design costs and limit the selection of drug-resistant virus variants.
Keywords: enterovirus; multi-target directed ligand; clinical trials; combination; drug design enterovirus; multi-target directed ligand; clinical trials; combination; drug design

Graphical Abstract

Share and Cite

MDPI and ACS Style

Roux, H.; Touret, F.; Rathelot, P.; Vanelle, P.; Roche, M. From the “One-Molecule, One-Target, One-Disease” Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections. Pharmaceuticals 2024, 17, 1218. https://doi.org/10.3390/ph17091218

AMA Style

Roux H, Touret F, Rathelot P, Vanelle P, Roche M. From the “One-Molecule, One-Target, One-Disease” Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections. Pharmaceuticals. 2024; 17(9):1218. https://doi.org/10.3390/ph17091218

Chicago/Turabian Style

Roux, Hugo, Franck Touret, Pascal Rathelot, Patrice Vanelle, and Manon Roche. 2024. "From the “One-Molecule, One-Target, One-Disease” Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections" Pharmaceuticals 17, no. 9: 1218. https://doi.org/10.3390/ph17091218

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop